A compound ensures the ALS-linked protein SOD1 and the respiratory enzyme COX are sated with the essential metal.
Attendees grapple with conflicting binding results
Scientists find evidence for an Aβ etiology distinct from Alzheimer’s after brain trauma.
Researchers failed to confirm a high-profile, previous 10-lipid panel, but remain bullish on the potential of blood-based metabolites as biomarkers.
Preliminary data suggests a long lag between Aβ and tau deposits as the disease develops.
In hopes of incorporating spatial navigation as an outcome measures in trials, a virtual version of the Morris water maze aims to bridge mouse and human therapy studies.
While regulators are trying to figure out what went wrong, independent chemists have dug into the mechanism of what may have been a "dirty" drug.
Scientists found Aβ pathology in the brains of young people who got brain tissue grafts from cadavers. In certain rare circumstances, β-amyloid appears to spread from brain to brain.
The death in January of a volunteer in a Phase 1 trial of a would-be pain and anxiety medication is the worst such disaster since 2006. The fiasco may lead to new safety recommendations for first-in-human drug studies, experts suggest. Some worry it could slow recruitment, already a problem for many Alzheimer’s studies. What is known about this drug? Read Madolyn Rogers’ in-depth coverage.
Though neurologists mostly focus on movement problems with ALS, they have come to realize that the mind, too, suffers in people with this disease. An epidemiological study in 274 people with ALS—a large group for such a rare condition—confirmed that about 60 percent had signs of cognitive difficulty, and about 30 percent had signs of behavioral changes such as apathy. In many participants, though they had been previously diagnosed only with ALS, the cognitive or behavioral symptoms were severe enough that the authors suspected they might have frontotemporal dementia, too. The changes in behavior, in particular, were associated with difficulty moving, speaking, or breathing.
Off-target troubles aside, tau tracers took the cake at the 10th Human Amyloid Imaging conference, held January 13 to 15 in Miami Beach, Florida. Even as researchers continue to sort out the vagaries of working with investigational tracers, they have started delving into deeper questions than whether neurofibrillary tangles are merely present in the brain. Scientists are asking how patterns of tau deposition relate to Aβ, neurodegeneration, and connectivity in Alzheimer’s disease. Preliminary cross-sectional data hint at a considerable lag between Aβ and tau accumulation in familial AD. New ligands debuted at HAI this year, but whether they will better detect tau deposits than the current batch remains to be seen. Leaders in the field still don’t know how well tau PET will work in other forms of dementia, such as FTD, PSP, and CBD.
- Mark Mapstone on Replication a Challenge in Quest for Alzheimer’s Blood Test
- Eugenia (Jania) Trushina on Replication a Challenge in Quest for Alzheimer’s Blood Test
- Li-Huei Tsai on Tet3 Reads 5-Carboxylcytosine through Its CXXC Domain and Is a Potential Guardian against Neurodegeneration.
- Bruce Yankner on Tet3 Reads 5-Carboxylcytosine through Its CXXC Domain and Is a Potential Guardian against Neurodegeneration.
- Dominic Walsh on News Brief: More Evidence for Aβ Spread Between People
- Colin Masters on News Brief: More Evidence for Aβ Spread Between People
- John Harrison on Treasure Hunt in Alzheimer’s Trials?
- Laura Goldstein on Confirmed: ALS Attacks Cognition and Behavior
- Ronald Glenn Thomas on Suzanne Hendrix on Constructing Composites for Trials in Early Alzheimer’s
- Christian Haass on TREM2 Goes Up in Spinal Fluid in Early Alzheimer’s
- Steve Barger on Vigorous Exercise: Could it Promote ALS in Women?